Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
What Makes Charles River (CRL) a New Buy Stock
Charles River (CRL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Charles River Laboratories International, Inc. (CRL) Hit a 52 Week High, Can the Run Continue?
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism
CORT's shares plunge after the FDA issues a CRL to relacorilant's new drug application for treating patients with hypercortisolism.
FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
Should You Continue to Hold CRL Stock in Your Portfolio for Now?
Charles River gains from strong RMS demand, strategic partnerships and solid finances but faces macro and competitive pressures in 2025.
Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Jefferies London Healthcare Conference 2025 Transcript
Charles River Laboratories International, Inc. ( CRL ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Birgit Girshick - Corporate Executive VP & COO Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division All right. Good morning, everybody.
Charles River (CRL) International Revenue Performance Explored
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Charles River Laboratories International, Inc. (CRL) Q3 2025 Earnings Call Transcript
Charles River Laboratories International, Inc. ( CRL ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foster - Chairman, President & CEO Michael Knell - Interim CFO, Corporate Senior VP & Chief Accounting Officer Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division David Windley - Jefferies LLC, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Justin Bowers - Deutsche Bank AG, Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Michael Ryskin - BofA Securities, Research Division Ann Hynes - Mizuho Securities USA LLC, Research Division Max Smock - William Blair & Company L.L.C.
Charles River: Mixed Q3 As Strategic Review Disappoints
Charles River Laboratories remains a "Hold" as strategic review yields minimal change and a sale is unlikely. CRL faces slow organic growth, shrinking backlog, and ongoing pressure in its core DSA segment, with limited near-term demand recovery. Cost-cutting, selective divestitures, and a new $1 billion buyback authorization offer some support, but growth headwinds persist.
Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
